Biocon shares drop 6% after USFDA inspection of Malaysian unit
The OAI status may cause delay or withholding of pending product approvals or supplements from the facility, Biocon says
biocon company
October 2023
August 2023
July 2023
May 2023
April 2023
September 2022
June 2022
February 2022
January 2022
December 2021
Biocon shares down 5% on 30% dip in Q1 profit
Biocon Ltd reported a decline in the net profit in the April to June quarter by 30% to ₹101.4 crore as against ₹144.40 crore in the same period last year.
Why Cancer Is The New Cardiology For Hospital Chains
India being the world's third-largest in cancer burden, oncology is now competing with cardiology in diagnosis, care and management at leading healthcare chains.
Biocon shares jump 7% on strong Q4, dividend declaration
Biocon declared a dividend of ₹1.50 per share for FY23, which includes payout on account of one-time exceptional gains arising from partial monetisation of its holdings in Syngene
Serum Institute to double its investment in Biocon subsidiary to $300 mn
As per the new arrangement, Biocon Biologics will have access to 100 million doses of vaccines annually together with the distribution rights to Serum Institute’s vaccine portfolio.
Sensex, Nifty to open lower; Tata Motors, RIL, IndiGo, NTPC, Biocon, Cipla shares in focus
The Sensex and Nifty are poised to open lower on Wednesday, in line with global equities amid concerns about aggressive interest rate hikes from the U.S. Federal Reserve.
Biocon says 'all product approvals are legitimate' in bribery case for insulin approval
CBI says the accused was trying to exert undue influence on officers of CDSCO to waive the Phase III trial of "Insulin Aspart Injection".
Covid-19 put spotlight on vaccines, diagnostics: Mazumdar-Shaw
Resurgence of interest and new technologies bring a huge opportunity for the vaccine development field, says Biocon CMD Kiran Mazumdar-Shaw.
Biocon developing 20 biosimilar products for global markets
Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products.
Biocon wins US patent battle against Sanofi on insulin biosimilar
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
